METASTATIC CELLS DETECTION IN LUNGS USING HP HE AND TARGETED CONTRAST AGENT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们开发了一种新的方法，使用超极化氦核磁共振和靶向造影剂来检测肺部转移的癌细胞。我们的目标是确定我们的方法相对于其他临床可用的技术，如PET和CT扫描的敏感性和特异性。我们计划在荷瘤小鼠注射我们的造影剂LHRH-Spion后对它们进行扫描。我们将利用10只已经用其他方式(CT和PET)成像并在肺部显示出转移癌细胞的迹象的乳腺肿瘤小鼠。我们要求额外的5天MRI时间来完成我们上面标题的试点项目。有了这段时间，我们希望为一份备受瞩目的出版物生成必要的数据，以及为R01应用程序生成初步数据。以下是到目前为止项目成就的更多细节。 根据美国癌症协会的数据，超过144万人将被诊断为癌症，今年美国将有超过56万人死于癌症。这些患者的高死亡率被归因于在更容易诊断的原发肿瘤的同时发生亚临床隐匿性微转移。因此，寻找这些微转移细胞是一个具有重大临床意义的问题。敏感的非侵入性方法对于早期转移性疾病检测和监测后续治疗都是必要的。 我们的研究重点是MRI对特定靶点肺转移瘤的检测。肺转移是常见的，最常见的是有丰富的全身静脉引流的肿瘤，如肾癌、骨肉瘤、绒毛膜癌、黑色素瘤、睾丸畸胎瘤和甲状腺癌。然而，大多数肺转移是由常见的肿瘤引起的，如乳腺癌、结直肠癌、前列腺癌、支气管癌、头颈癌和肾癌，当然还有肺癌。在所有死于癌症的患者中，有20%-54%存在肺转移，而肺转移的检测在癌症患者的治疗中至关重要。当前的筛查技术 在肺部(细针抽吸(FNA)、支气管镜检查、痰细胞学、PET和CT检查)是侵袭性的和/或缺乏检测肺部微转移、单个播散细胞或小肿瘤细胞团所需的灵敏度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We developed a new method that uses Hyperpolarized Helium MRI and targeted contrast agent to detect metastatic cancer cells in lungs. We aim to establish the sensitivity and specificity of our method with respect to other clinically available techniques, such as PET and CT scan. We plan on scanning breast tumor bearing mice after they received an injection of our contrast agent LHRH-SPION. We will utilize 10 breast tumor mice that have already been imaged with other modalities (CT and PET) and have shown sign of metastatic cancer cells in lungs.We are requesting 5 days of additional MRI time to complete our pilot project of the title above. With this time we expect to generate the necessary data for a high-profile publication, as well as preliminary data for an R01 application. Below are additional details about the project achievements thus far. According to the American Cancer Society, more than 1.44 million people will be diagnosed with cancer, and more than 560 thousand will die of it this year in the US. The high mortality rate in these patients has been attributed to the development of subclinical occult micrometastasis simultaneously with the more easily diagnosed primary tumor. Thus, the search for these micrometastatic cells is an issue of significant clinical interest. Sensitive non-invasive methods are needed both for early metastatic disease detection and to monitor subsequent treatments. We are focusing our investigation on the MRI detection of specifically targeted pulmonary metastases. Pulmonary metastases are common and most frequently occur with tumors that have rich systemic venous drainage, like renal cancers, bone sarcomas, choriocarcinomas, melanomas, testicular teratomas, and thyroid carcinomas. However most pulmonary metastases arise from common tumors, such as breast, colorectal, prostate, bronchial, head-and-neck, and renal and, of course, lung cancers. Pulmonary metastases are present in 20-54% of all patients who die of cancer, and detection of pulmonary metastases is crucial in the treatment of patients with cancer. Current screening techniques in lungs (fine-needle aspiration (FNA), bronchoscopy, sputum cytology, PET, and CT are invasive and/or lack the sensitivity necessary to detect micrometastases, single disseminated cells, or small tumor cell clusters in lungs.